INTANGIBLE ASSETS AND GOODWILL (Tables)

9 Months Ended

Sep. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of net-book value and estimated remaining life and finite lived intangible assets

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of September 30, 2021:


(In thousands)	Weighted Average Remaining Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net Balance at September 30, 2021
Finite-lived intangible assets
Trade name	14.1	$	100,700	$	(11,980)	$	88,720
Customer relationships	12.0	2,700		(539)		2,161
Patents	3.0	10,442		(6,427)		4,015
Acquired developed technology	8.4	853,171		(155,404)		697,767
Supply agreements	5.7	2,295		—		2,295
Total finite-lived intangible assets		969,308		(174,350)		794,958
In-process research and development	n/a	1,250,000		—		1,250,000
Total intangible assets		$	2,219,308	$	(174,350)	$	2,044,958

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2020:


(In thousands)	Weighted Average Remaining Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net balance at December 31, 2020
Finite-lived intangible assets
Trade name	14.9	$	100,700	$	(7,258)	$	93,442
Customer relationships	12.8	2,700		(404)		2,296
Patents	3.7	10,441		(5,422)		5,019
Acquired developed technology	9.0	814,171		(93,278)		720,893
Supply agreements	6.5	30,000		(4,527)		25,473
Total intangible assets		$	958,012	$	(110,889)	$	847,123

Schedule of estimated future amortization expense, intangible assets

As of September 30, 2021, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:


(In thousands)
2021 (remaining three months)	$	23,053
2022	92,205
2023	92,202
2024	91,868
2025	90,820
Thereafter	404,810
	$	794,958

Schedule of carrying amount of goodwill

The change in the carrying amount of goodwill for the periods ended September 30, 2021 and December 31, 2020 is as follows:


(In thousands)
Balance, January 1, 2020	$	1,203,197
Paradigm & Viomics acquisition	30,431
Genomic Health acquisition adjustment (1)	4,044
Balance, December 31, 2020	$	1,237,672
Thrive acquisition	948,105
Ashion Acquisition	56,758
Balance September 30, 2021	$	2,242,535

______________

(1)The Company recognized a measurement period adjustment to goodwill related to an increase in Genomic Health’s pre-acquisition deferred tax liability due to finalization of certain income-tax related items.